Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active th (Q33393031)
Jump to navigation
Jump to search
scientific article
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active th |
scientific article |
Statements
1 reference
Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active th (English)
1 reference
Agnieszka Jagiello-Gruszfeld
0 references
Guido Sauter
1 reference
John R Mackey
1 reference
Michael F Press
1 reference
Henry Taupin
1 reference
Janusz Rolski
1 reference
Vicente Valero
1 reference
Mark D Pegram
1 reference
Dennis J Slamon
1 reference
John Forbes
1 reference
Henri Roche
1 reference
John Crown
1 reference
Pierre Fumoleau
1 reference
Zrinka Mrsic-Krmpotic
1 reference
Alessandro Riva
1 reference
29 November 2010
1 reference
1 reference
29
1 reference
149-156
1 reference
Identifiers
1 reference
1 reference